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In ThIs Issue
•	 estrogen Receptor Gene 
Polymorphisms and Lung 
Adenocarcinoma Risk in 
never-smoking Women
The study assessed the relationship between estrogen 
receptor (ER) gene polymorphism and lung cancer 
risk in 532 never-smoking female patients and 532 
healthy controls. The ESR1 and ESR2 single nucleotide 
polymorphism (SNP) data from a genome-wide 
association study were used in this analysis. Expression 
quantitative trait loci (eQTL) analysis was conducted 
to determine functional roles of the ER gene SNPs. 
rs7753153 and rs985192 of ESR1, and rs3020450 
of ESR2 were associated with lung cancer risk 
(rs7753153: odds ratio [OR]: 1.509; rs985192: OR: 
1.309; rs3020450: OR: 2.110). Significantly higher 
risk for lung cancer was observed in subjects harboring 
at-risk genotypes but without hormone replacement 
therapy (HRT) versus those without at-risk genotypes 
treated with HRT (rs7753153 GG, OR: 2.133; rs985192 
AA/AC, OR: 1.752; rs3020450 AG/GG, OR: 7.162). 
Decreased ESR1 expression was associated with risk 
genotypes of rs7753153 (p=0.0248) and rs9479122 
(p=0.0251). In summary, the findings demonstrated 
an association between ER gene SNPs and lung 
cancer risk in never-smoking women, and the crucial 
gene-environment interaction in lung carcinogenesis 
implicated by the effects of ER gene SNPs and HRT use 
on lung cancer risk. (p. 1413)
•	 The 2015 WhO 
Classification of Tumors 
of the Thymus: Continuity 
and Changes
revision and refinement of diagnostic criteria for type 
A, AB, B1–B3 thymomas and thymic squamous cell 
carcinoma to improve the reproducibility of thymoma 
subtyping, the distinction between thymomas and 
thymic carcinomas, and their clinical relevance. The 
interdisciplinary perspective of the classification has 
been strengthened by involving clinical experts from 
radiology, thoracic surgery, and oncology in addition 
to incorporating state-of-the-art positron emission 
tomography/computed tomography images, and 
depicting prototypic cytological specimens. The new 
WHO Classification therefore represents an important 
tool for pathologists, cytologists and clinicians. Its 
influence on therapeutic decisions for thymic epithelial 
tumors and mediastinal lymphomas, future perspectives 
and challenges were also discussed. (p. 1383)
In ThIs Issue/ReseARCh WATCh/neWs In BRIef/neWs fROm The  
IAsLC TOBACCO COnTROL COmmITTee
This overview of the 4th edition of the World Health Organization 
(WHO) Classification of thymic tumors described the established 
and new tumor entities and variants of thymic epithelial tumors, 
germ cell tumors, lymphomas, dendritic cell and myeloid 
neoplasms, and soft-tissue tumors of the thymus and mediastinum. 
It also focuses on the major differences between the 3rd and 4th 
edition of the WHO Classification at immunohistochemical, genetic 
and conceptual levels. Another focus of the 4th edition was the 
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ReseARCh WATCh
•	 Afatinib versus erlotinib 
as second-Line Treatment 
of Patients with Advanced 
squamous Cell Carcinoma 
of the Lung (LuX-Lung 8):  
An Open-Label 
Randomized Controlled 
Phase 3 Trial
This trial comparing afatinib (irreversible ErbB family 
blocker) with erlotinib (reversible EGFR tyrosine kinase 
inhibitor) was conducted in 795 patients with stage IIIB 
or IV squamous cell lung carcinoma and prior platinum-
based chemotherapy in 183 cancer centers across 23 
countries. Primary analysis of progression-free survival 
(PFS) at a median follow-up of 6.7 months demonstrated 
significantly prolonged PFS in the afatinib arm versus 
the erlotinib arm (median 2.4 months vs. 1.9 months; 
hazard ratio [HR] 0.82; p = 0.0427). In the primary 
analysis of overall survival (OS) at a median follow-up 
of 18.4 months, the afatinib arm achieved significantly 
improved OS (median 7.9 months vs. 6.8 months; HR 
0.81; p = 0.0077), PFS (median 2.6 months vs. 1.9 
months; HR 0.81; p = 0.0103), and disease control (51% 
vs. 40%; p = 0.0020). Similar adverse events were found 
in both arms, except for higher frequency of drug-related 
grade 3 diarrhea and stomatitis with afatinib (10% vs. 
2% and 4% vs. 0, respectively), and grade 3 rash or 
acne with erlotinib (6% vs. 10%). All in all, the findings 
suggest afatinib to be a potential treatment for squamous 
cell lung carcinoma, which provides significant 
improvement of PFS and OS, with tolerable toxicity and 
the convenience of oral administration.
Soria J-C, Felip E, Cobo M, et al. Afatinib versus 
erlotinib as second-line treatment of patients with 
advanced squamous cell carcinoma of the lung (LUX-
Lung 8): an open-label randomised controlled phase 3 
trial. The Lancet Oncology 2015;16:897–907.
was used to measure clinical responses, which were 
expressed as percent tumor shrinkage. The PCR and 
NGS assays achieved a sensitivity of 72% and 100%, 
respectively, and a specificity of 74% and 100%, 
respectively. Significant correlation in quantitative 
indices was established between PCR and NGS assays 
(p < 0.001). EGFR testing at baseline and serially 
at 4 to 60 days demonstrated 95% of patients with a 
progressive decrease in SQI (from day 4) on tyrosine 
kinase inhibitor treatment. The rate of SQI decrease was 
significantly associated with percent tumor shrinkage at 
2 months (p < 0.0001), which exceeded 50% in 70% of 
patients, who were rapid responders, at 14 days. Early 
T790M mutations were absent from plasma of rapid 
responders while early increase in circulating levels 
were found in 2 slow responders. To conclude, the 
findings suggest that quantification of plasma mutant 
EGFR using a standardized PCR assay is feasible. The 
strong correlation between plasma EGFR SQI in the 
first days of treatment and clinical response indicates 
its potential diagnostic value and warrants prospective 
clinical studies to confirm the data. (p. 1437)
•	 early Prediction of 
Response to Tyrosine 
Kinase Inhibitors by 
Quantification of eGfR 
mutations in Plasma of 
nsCLC Patients
This study aimed to evaluate the feasibility of detecting plasma 
epidermal growth factor receptor (EGFR) mutations in non-small 
cell lung cancer patients and to correlate mutant EGFR levels 
during the first days of EGFR TKI therapy with clinical response. 
A standardized allele-specific polymerase chain reaction (PCR) 
test and ultra-deep next-generation sequencing (NGS) were utilized 
to detect plasma EGFR mutations in 69 EGFR-mutant positive 
patients and 21 negative controls. A semiquantitative index (SQI), 
derived from dilutions of known EGFR mutation copy numbers, 
was reflective of proportion of mutated versus wild-type copies of 
EGFR. Response Evaluation Criteria in Solid Tumors 1.1 criteria 
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region of the genome), which led to cyclin D1 
overexpression. This suggests an alternative mechanism 
of Rb1 inhibition and further implicates the loss of TP53 
and RB1 as an obligatory step in SCLC development. 
Somatic genomic rearrangements of TP73 were also 
uncovered, resulting in an oncogenic TP73Δex2/3. 
In some individual patients, SCLC tumors harbored 
kinase gene mutations, presenting potential therapeutic 
strategies for these patients. A pattern of high level of 
neuroendocrine marker genes was observed in SCLC, 
correlated with inactivating mutations in NOTCH family 
genes found in 25% of SCLC. An in vivo model of 
SCLC showed that Notch signaling activation disrupted 
neuroendocrine gene expression, reduced the number 
of tumors and prolonged survival. Taken together, 
this first comprehensive genomic profiling of SCLC 
demonstrated a number of genes and pathways that 
could be targeted for therapeutic intervention against 
this aggressive cancer.
George J, Lim JS, Jang SJ, et al. Comprehensive 
genomic profiles of small cell lung cancer. Nature 
2015;524:47–53.
•	 Cigarette smoking 
Cessation Attempts Among 
Current us smokers 
Who Also use smokeless 
Tobacco
Using data from the 2010–2011 Tobacco Use 
Supplement to the Current Population Survey (current 
cigarette smokers = 26,760), researchers compared 
dual users of cigarettes and smokeless tobacco (n = 
675) with exclusive smokers for their cigarette smoking 
cessation attempt of the past year. Dual users were 
more likely to have attempted to quit cigarette smoking 
versus exclusive smokers (45% vs. 37%; p < 0.01); the 
same was observed after adjustment for demographic 
differences and cigarette dependence levels (OR
adj
 1.33). 
Dual users who tried to quit switched to smokeless 
tobacco (48%), and relapsed more quickly than 
exclusive smokers (HR
adj
 1.13) once in a quit attempt. 
No difference was observed in 30-day abstinence 
rates on the most recent quit attempt (OR
adj
 1.09). 
Cigarette consumption level was the best predictor of 
past 30-day abstinence in both groups. In summary, 
the findings indicated that dual users are more likely to 
attempt smoking cessation, but relapse more quickly 
than exclusive smokers, and are not more likely to 
accomplish 30-day smoking cessation.
Messer K, Vijayaraghavan M, White MM, et al. 
Cigarette smoking cessation attempts among current 
US smokers who also use smokeless tobacco. Addictive 
behaviors 2015;51:113–119.
•	 Comprehensive Genomic 
Profiles of small Cell Lung 
Cancer
A large, international group of researchers led by Roman Thomas 
from Cologne, Germany conducted whole genome sequencing 
of 110 small cell lung cancers (SCLC). The results revealed a 
high overall mutation rate in these tumors (average 8.62 non-
synonymous mutations per million base pairs) and a high proportion 
of C:G>A:T transversions known to be induced by smoking. 
Genetic heterogeneity in SCLC was less diverse than those in lung 
adenocarcinoma and was independent of clinical stage. In almost all 
the SCLC tumors analyzed, the tumor suppressor genes TP53 and 
RB1 were both inactivated, with complex genomic rearrangements 
sometimes. Two tumors with wild-type RB1 demonstrated 
chromothripsis (many chromosomal rearrangements in a localized 
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p < 0.001). Patients diagnosed with lung cancer and 
those without private health insurance were more 
likely to smoke (OR = 2.84; p < 0.001 and OR = 3.34; 
p < 0.001, respectively). In summary, continued 
smoking at average 13 months after diagnosis was 
reported in a small part of the study population. 
Younger patients diagnosed with lung cancer and with 
lower socioeconomic status are at risk, and should be 
specifically targeted to receive smoking cessation advice 
and intervention.
Regan T, Carey M, Bryant J, et al. Prevalence and 
correlates of current smoking among medical oncology 
outpatients. Psycho-Oncology, n/a-n/a, doi:10.1002/
pon.3893 (2015).
•	 Prevalence and Correlates 
of Current smoking 
Among medical Oncology 
Outpatients
neWs In BRIef
•	 Gefitinib Approved for 
EGFR-mutated metastatic 
non–small Cell Lung 
Cancer
Gefitinib was approved by the FDA for the treatment 
of patients with metastatic non-small cell lung cancer 
(NSCLC) harboring EGFR exon 19 deletions or exon 
21 substitution mutations as detected by the companion 
diagnostic test, therascreen EGFR RGQ PCR Kit. 
The approval was based on the data of a clinical study 
that showed an objective response rate of 50% by a 
blinded independent central review (median duration 
of response = 6.0 months), and 70% by investigator 
assessment (median duration of response = 8.3 months). 
An exploratory analysis of a subset of a randomized 
trial demonstrated a median progression-free survival of 
10.9 months in patients treated with gefitinib versus 7.4 
months in patients treated with carboplatin/paclitaxel 
(hazard ratio = 0.54).
Image credit: Maggie Bartlett | National Human 
Genome Research Institute
•	 european Commission 
Approves nivolumab 
for Previously-Treated 
Advanced squamous non-
small Cell Lung Cancer
The European Commission has approved nivolumab 
for the treatment of locally advanced or metastatic 
squamous non-small cell lung cancer (NSCLC) 
following prior chemotherapy. Nivolumab is the first 
PD-1 immune checkpoint inhibitor approved in the 
European Union for lung cancer, and represents the 
first major advance in treatment for the disease in 
more than a decade. The approval was based on the 
findings from CheckMate-017 and -063 trials. The 
phase III CheckMate-017 study demonstrated that 
nivolumab achieved a 41% reduction in risk of death, a 
significantly superior 1-year overall survival (OS) rate 
of 42% vs. 24% for docetaxel, and a durable antitumor 
activity. Nivolumab in the phase II CheckMate-063 
study showed an estimated 41% 1-year survival rate and 
a median OS of 8.2 months. Safety profile of nivolumab 
is consistent with previous trials and favorable versus 
docetaxel.
Image source: National Cancer Institute
The study assessed the prevalence of self-reported current smoking 
and the associated demographic and psychosocial factors in a 
survey of 1338 medical oncology outpatients (aged ≥18 years) 
across Australia. The analysis demonstrated a prevalence of  
10.9% in current smoking (n = 146). The adjusted prevalence  
was significantly lower in patients aged ≥65 years (OR = 0.27;  
p < 0.001), and those without health concession cards (OR = 0.36; 
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•	 Cytosponge Could 
help early Detection of 
esophageal Cancer
Researchers at the University of Cambridge developed 
the Cytosponge in a pill, which dissolves when 
swallowed to reveal a sponge that allows collection of 
cells from all along the gullet, compared with standard 
biopsies that collect individual point samples. Whole-
genome sequencing was conducted to analyze 23 paired 
Barrett’s esophagus and esophageal adenocarcinoma 
(EAC) samples, as well as 73 samples from one 
patient with Barrett’s esophagus over 3 years. The 
study, published in Nature Genetics, demonstrated that 
Barrett’s esophagus is polyclonal and highly mutated 
even without dysplasia; EAC has marked increase 
in copy number versus Barrett’s esophagus; little 
mutational overlap between EAC and adjacent Barrett’s 
esophagus; mutational context is mostly common from 
non-dysplastic Barrett’s esophagus to EAC suggesting 
common mutagens throughout disease progression. The 
findings suggest that histopathological examination of 
dysplasia poorly reflects the molecular aberrations in 
Barrett’s epithelium. The Cytosponge provides unbiased 
sampling that reflects the entire clonal architecture, and 
has identified molecular alterations that could contribute 
to the progression from Barrett’s esophagus to EAC. 
Further studies are warranted to confirm and identify 
specific biomarkers to aid early detection.
Image credit: Nephron | CC BY-SA 3.0
agreements such as the WTO Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS 
Agreement), the Paris Convention of Industrial Property 
and the WTO Agreement on Technical Barriers to Trade. 
The letter also claims that “Plain Packaging Destroys 
the Value of Trademarks without Advancing Public 
Health Objectives”. The first part of that claims sounds 
just like Philip Morris Asia’s challenge to Australia’s 
plain packaging legislation (http://www.ag.gov.au/
tobaccoplainpackaging), a challenge which struggles 
along even after the High Court of Australia ruled that the 
Tobacco Plain Packaging Act 2011 is not unconstitutional 
and even, despite the letter’s claims, after evidence has 
emerged to show the beneficial effect of plain packaging 
on smoking rates,2 an increase in cost of cigarettes3 and 
no evidence of an increase in the use of illicit forms of 
tobacco.4 The Chamber’s support for similar objectives 
held by Big Tobacco has lost it one friend. The CVS 
Health Corporation, which this column has applauded 
in the past for removing tobacco products from its stores 
(IASLC Tobacco Control Committee Newswatch June 
2014), has announced that it would resign from the US 
Chamber of Commerce because of this issue.
neWs fROm The IAsLC 
TOBACCO COnTROL 
COmmITTee
•	 Big Tobacco is everywhere
A New York Times article reports that the Chamber of Commerce, 
which bills itself as the “world’s largest business organization 
representing the interests of more than 3 million businesses” (www.
uschamber.com), was participating and driving a global campaign 
to counter anti-smoking laws.1 One of the measures employed by 
the Chamber was to write to many countries (with big efforts in 
high smoking countries) opposing various measures to restrict the 
tobacco industry. This includes a May 2011 letter from the Senior 
Vice-President, Myron A. Brilliant, to the Tobacco Reform Section 
of the Department of Health and Ageing in Canberra that quotes, 
among various things, Australia’s “obligations” under international 
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Congratulations to Austria, for passing a complete 
smoking ban in restaurants and other food providers, 
to start May 1, 2018.5 The report on Tourism-Review.
com highlights the smoking bans for guest rooms, all 
public places centred on food and drink consumption 
and the potential for creation of smoker’s rooms. There 
is controversy over this; the report quotes support for the 
move as well as opposition. It neatly categorises Austria 
as “Europe’s ashtray”, perhaps not surprising given 
the WHO smoking rates in Austria of 38.9% overall6 
compared with 24% in near neighbours Germany and 
Switzerland (2012 data), around 20% in the UK (2014 
data), 17.8% in the USA (2014 data) and 15% (2012 
data) in Australia.6
1.  Making Tobacco’s Case. Available at http://
www.nytimes.com/interactive/2015/06/29/us/
us-chamber-commerce-cigarette-lobbying.html.
2.  Tobacco key facts and figures. Available at http://
www.health.gov.au/internet/main/publishing.nsf/
content/tobacco-kff>.
3.  Scollo M, Zacher M, Coomber K, et al. Changes 
in use of types of tobacco products by pack sizes 
and price segments, prices paid and consumption 
following the introduction of plain packaging in 
Australia. Tob. Control 2015;24:ii66–ii75.
4.  Scollo M, Zacher M, Coomber K, Wakefield M. 
Use of illicit tobacco following introduction of 
standardised packaging of tobacco products in 
Australia: results from a national cross-sectional 
survey. Tob. Control 2015;24:ii76–ii81.
5.  Austria: No Smoking in Local Restaurants. 
TOURISM REVIEW. Available at http://www.
tourism-review.com/austria-no-smoking-in-
local-restaurants-news4640.
6.  WHO | Tobacco control country profiles. WHO. 
Available at http://www.who.int/tobacco/
surveillance/policy/country_profile/en/.
•	 Glückwünsche Austria
Image credit: Emily Stone | No smoking except in 
the Sonnenbar, Austria 2014.
Image credit: Emily Stone | Cigarette vending 
machine, Austria 2014.
